Sickle Cell Disease
The most widespread genetic disease in the world
A disease that challenges life on a daily basis
Vaso-occlusive crises are unpredictable, extremely painful (often requiring hospitalization), and their complications can be life-threatening.
Sickle cell disease — a burden for patients and society
Cost of screening, monitoring, and treatment: $3.1 billion in 2024
Estimated at $7.4 billion by 2030
A heavy economic impact on public health systems
Our value proposition
With DYNARED technology, we aim to provide clinicians with a powerful and rapid biomarker to improve patient monitoring, assess the severity of vaso-occlusive crises, and reduce the overall burden of sickle cell disease.
There is still a missing essential biomarker to assess the health status of sickle cell patients.
Pr Catherine Badens